I think its safe to say NEU management when negotiating the deal would have gone over all possible scenarios with regard to Nuplazids prospects and the possible implications for Trofinatide p3 trials.
They were obviously comfortable with it, although like others have said it would be good to get some clarification from management.
Ann: Change of Director's Interest Notice, page-17
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.80 |
Change
-0.830(5.31%) |
Mkt cap ! $1.924B | |||
| Open | High | Low | Value | Volume |
| $15.65 | $15.72 | $14.76 | $11.61M | 772.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 12031 | $14.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.84 | 734 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |